Related Articles
ALK‑positive locally advanced lung cancer in a patient who achieved long‑term complete response with crizotinib: A case report
Long‑term complete response in a patient with postoperative recurrent ALK‑rearranged lung adenocarcinoma treated with crizotinib: A case report
Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report
Crizotinib-associated toxic epidermal necrolysis in an ALK-positive advanced NSCLC patient
Alectinib as a treatment option following recovery from crizotinib‑induced interstitial lung disease in patients with anaplastic lymphoma kinase‑positive advanced non‑small‑cell lung cancer